Precision BioSciences (DTIL) EBITDA Yield: History & Chart

Precision BioSciences, Inc.(DTIL)

Biotechnology · Durham, NC

$6.28-0.03 (-0.48%)

Delayed quote: Oct 6, 2026, 9:40 AM EDT

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.

Durham, NC

67 employees

www.precisionbiosciences.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael Amoroso

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Precision BioSciences, Inc. (DTIL)	$173.34M	N/A	N/A	N/A	N/A
Compass Therapeutics, Inc. (CMPX)vs ›	$171.61M	N/A	N/A	N/A	N/A
Coherus Oncology, Inc. (CHRS)vs ›	$169.95M	N/A	12.03%	9.31%	9.31%
Cue Biopharma, Inc. (CUE)vs ›	$177.29M	N/A	N/A	N/A	N/A
Canton Strategic Holdings Inc (CNTN)vs ›	$178.54M	N/A	N/A	N/A	N/A
Journey Medical Corporation (DERM)vs ›	$183.71M	0.69%	0.65%	2.68%	2.68%
Inogen, Inc. (INGN)vs ›	$161.12M	N/A	4.75%	3.30%	2.87%
ALX Oncology Holdings Inc. (ALXO)vs ›	$158.25M	N/A	N/A	N/A	N/A
Cardiol Therapeutics Inc. (CRDL)vs ›	$155.04M	N/A	N/A	N/A	N/A
Anavex Life Sciences Corp. (AVXL)vs ›	$154.76M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA YIELD

TTM

Precision BioSciences, Inc. (DTIL)

$173.34M

N/A

Compass Therapeutics, Inc. (CMPX)vs ›

$171.61M

N/A

Coherus Oncology, Inc. (CHRS)vs ›

$169.95M

N/A

12.03%

9.31%

Cue Biopharma, Inc. (CUE)vs ›

$177.29M

N/A

Canton Strategic Holdings Inc (CNTN)vs ›

$178.54M

N/A

Journey Medical Corporation (DERM)vs ›

$183.71M

0.69%

0.65%

2.68%

Inogen, Inc. (INGN)vs ›

$161.12M

N/A

4.75%

3.30%

2.87%

ALX Oncology Holdings Inc. (ALXO)vs ›

$158.25M

N/A

Cardiol Therapeutics Inc. (CRDL)vs ›

$155.04M

N/A

Anavex Life Sciences Corp. (AVXL)vs ›

$154.76M

N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

DTIL EBITDA Yield Metrics

DTIL Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics